But I wonder if SNY would cease promoting the branded Lovenox altogether?
SNY drastically scaled back the promotion of branded Lovenox in 2010 when NVS/MNTA got FDA approval, so there is little additional cost saving SNY can do.
…the distinction of who is selling the AG matters? To the best of my knowledge the MNTA-Sandoz contract has no regard to who is selling it.
Correct and crystal clear. Unlike the discussion we had about a fixed vs variable threshold for the profit-share mode under an AG, the lack of distinction in the NVS-MNTA Lovenox agreement about who sells the AG does not require any decoding of the redacted text.